Cleveland Diagnostics, Inc.

Cleveland Diagnostics, Inc. is a molecular diagnostics company specializing in blood-based cancer biomarker testing. The company develops and commercializes the IsoClear™ platform, a proprietary protein structural analysis technology that measures biomarker characteristics to identify cancer cell origin and distinguish aggressive disease from benign conditions. Their flagship product, IsoPSA, is a blood test for prostate cancer risk stratification that demonstrates superior specificity (2–3 times higher) compared to traditional PSA testing and reduces unnecessary prostate biopsies by up to 55% according to published clinical data. The IsoClear platform is designed to enable rapid development of a portfolio of affordable, accessible blood tests across multiple cancer types. Cleveland Diagnostics operates laboratory testing services from their Cleveland, Ohio headquarters and serves urology and oncology practices, hospital systems, and health systems nationwide. The company focuses on early cancer detection and risk assessment for high-grade disease, offering clinicians improved diagnostic clarity to guide treatment decisions and reduce patient harm from overdiagnosis and unnecessary interventions.